GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of GH Research (NASDAQ:GHRS) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock. HC Wainwright also issued estimates for GH Research’s Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.49) EPS and FY2029 earnings at $0.10 EPS.

Separately, Canaccord Genuity Group reduced their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.

GH Research Stock Performance

Shares of GHRS opened at $9.43 on Monday. The company’s fifty day moving average is $8.38 and its 200 day moving average is $8.92. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $14.99. The stock has a market capitalization of $490.64 million, a PE ratio of -11.94 and a beta of 0.84.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its stake in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).